The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 18, 2016
View Complete Issue         Table of Contents 2019 
Asfotase Alfa (Strensiq) for Hypophosphatasia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Asfotase Alfa (Strensiq) for Hypophosphatasia (online only)
July 18, 2016 (Issue: 1499)
The FDA has approved asfotase alfa (Strensiq – Alexion), a recombinant form of tissue-nonspecific alkaline phosphatase, for subcutaneous treatment of perinatal-, infantile-, and juvenile-onset hypophosphatasia. Asfotase alfa is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Asfotase Alfa (Strensiq) for Hypophosphatasia (online only)
Article code: 1499e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.